12 month price target, page-17

Good Job GKM and TDA (and anyone I missed) with the thorough reviews,

I have been really interested in TIS for a while and asked many doctors and others with a medical background to have a look into the product. The feedback I get is really positive however the majority say that in this industry the most important aspect is the promotion. In this regards, the commercial partner of TIS which is expected to eventuate in 3 months is by far the company maker in my eyes.

Though future price targets are exciting as is envisaging a market capitalsation in the billions or even thinking that TIS is the next COH (lol for later), what is important is to consider is how the future news will affect the current market capitalisation.

What TIS has is a multi-purpose and easily applied product that has shown excellent results consistently. The current market capitalisation is just under 100 million which I believe is appropriately undervalued. As everyone knows, TIS is tightly held and when the strategic partner comes on board I would not be surprised if the market cap is in excess of 300 million.

Overall, the real move for this company, should come after the EU human trial; thus on the success of the clinical trial, I would not be surpised if TIS approaches the near end of a billion dollar market cap towards the end of the year. Important stages for TIS:

1. Commercial Partner
2. Success of Patient Trial

Now Im going to do a very rough comparison between COH and TIS:

Number of Shares on issue:
COH: 50 million
TIS: 175 million - more than 3 times COH

Market Capitalisation:
COH: $4.629 billion @80 dollars a share - 48 times the size of TIS
TIS: $96 million @ 70 cents a share

Dividends:
COH: nearly 2 dollars (goes to show what TIS could be like in 10 years); payout ratio is 70%
TIS: Nil - but in 5 years?

Target Product:
COH: Impaired Hearing - Operation 1-5 hours
TIS: Diabetics, Burns, Correction of Wound Tissue - many options - walk into chemist and self application

Number of people suffering world wide:
COH: lets say 25% which is reasonable estimate from the first 5 google sites and the COH website
TIS: 20% (from TDAs post above)

Product Cost per implant/ treatment:
COH: $60,000 http://en.wikipedia.org/wiki/Cochlear_implant
TIS: 20-30 dollars

Product distribution:
COH: world-wide though some may not be able to afford cost
TIS: world-wide but much more affordable

Does TIS look undervalued??????

If TIS went up 10 fold to a market cap of 1.75 billion based on the success of the two above events and beginning sales towards the latter end of 2011 and early 2012 - which is possible, then in my opinion this would still look undervalued when thinking COH's expensive application, market cap, and the distribution potential and affordability of the VitroGro.

Promotion is Key = Commercial Partner = Key.

DYOR and looking for entry middle of January.